Annovis Bio (ANVS) Amortization of Deferred Charges (2019 - 2020)
Annovis Bio (ANVS) posted Amortization of Deferred Charges of $129.0 for Q1 2020, down 65.87% sequentially from $378.0 in Q4 2019, and up 15.18% YoY from $112.0 in Q2 2019.
Annovis Bio (ANVS) Amortization of Deferred Charges (2019 - 2020) Analysis & Trends
Annovis Bio has reported Amortization of Deferred Charges for 2 years, with the latest figure at $129.0 in Q1 2020.
- Quarterly Amortization of Deferred Charges rose 15.18% year-over-year to $129.0 in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $129.0 (down 89.17% YoY) and the FY2020 annual result came in at $129.0, down 89.17% from the prior year.
- Amortization of Deferred Charges slipped to $129.0 in Q1 2020 per ANVS's latest filing, from $378.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $378.0 in Q4 2019 and troughed at $112.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 129.00 |
| Mar 31, 2020 | 129.00 |
| Dec 31, 2019 | 378.00 |
| Dec 31, 2019 | 378.00 |
| Sep 30, 2019 | 368.00 |
| Sep 30, 2019 | 368.00 |
| Jun 30, 2019 | 333.00 |
| Jun 30, 2019 | 333.00 |
| Mar 31, 2019 | 112.00 |
| Mar 31, 2019 | 112.00 |